

# Nixon & Vanderhye P.C.

ATTORNEYS AT LAW

8TH FLOOR  
1100 NORTH GLEBE ROAD  
ARLINGTON, VIRGINIA 22201-4714

TELEPHONE: (703) 816-4000  
FACSIMILE: (703) 816-4100

## FACSIMILE COVER SHEET

**PLEASE DELIVER IMMEDIATELY!!!!**

*Copy*

Our Ref: 117 - 231

Your Ref: SN 08/776,350

Date: June 5, 1997

TO: Susan Unger

FIRM: US PTO

FACSIMILE NO.: 308-4242

FROM: Art Crawford

NUMBER OF PAGES (INCLUDING COVER SHEET): 5

(IF YOU DO NOT RECEIVE ALL OF THE PAGES OR ENCOUNTER DIFFICULTIES IN TRANSMISSION, PLEASE  
CONTACT US IMMEDIATELY AT (703-816-4000).

—  
FACSIMILE OPERATOR

ATTACHMENT/S: Copy - Preliminary Amendment

**OFFICIAL**

MESSAGE: As requested this morning.

*FAX CENTER  
RECEIVED  
JUN 05 1997  
GROUP 1800*

### CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by

0089516.01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**MACLEAN et al**

(National Phase PCT/GB95/01791)

Atty. Ref.: 117-231

Serial No. (To Be Assigned)

Group:

Filed: 28 January 1997

Examiner:

For: TREATMENT OF CANCER USING HSV MUTANT

\*\*\*\*\*

January 28, 1997

Honorable Commissioner of Patents  
and Trademarks  
Washington, DC 20231FAX CENTER  
RECEIVED

JUN 05 1997

GROUP 1800

Sir:

In order to place the above-identified application in better condition for examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please delete Claims 1 through 19 without prejudice.

PLEASE ADD THE FOLLOWING NEW CLAIMS -- 20 THROUGH 42 --

-- 20. A method of treating a secondary metastatic tumor in the central nervous system of a mammal, which method comprises the step of administering to the said mammal an effective amount of a mutant herpes simplex virus type 1 which has a non-functional  $\gamma$ 34.5 gene in the long repeat region ( $R_L$ ).